Previous close | 0.1600 |
Open | 0.1600 |
Bid | 0.1550 x 197574900 |
Ask | 0.1600 x 26031200 |
Day's range | 0.1500 - 0.1600 |
52-week range | 0.1000 - 0.9800 |
Volume | |
Avg. volume | 190,658 |
Market cap | 16.512M |
Beta (5Y monthly) | 1.94 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1390 |
Earnings date | 16 Aug 2022 - 22 Aug 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
BELLEVUE, Wash., May 09, 2022 (GLOBE NEWSWIRE) -- Medical device manufacturer, Nuheara Limited (ASX:NUH) (Company or Nuheara) is pleased to announce a series of structural changes designed to advance the Company’s unique and growing US based hearing healthcare market opportunities: The appointment of John R. Luna as its global, US based, Chief Executive Officer;Co-founder and former CEO, Justin Miller, remaining as the Company’s Managing Director;Engagement of Roth Capital Partners LLC (“Roth”)
BELLEVUE, Wash., April 12, 2022 (GLOBE NEWSWIRE) -- Nuheara Limited (ASX:NUH) (Company or Nuheara) has taken the final step in its plans to secure U.S. Food and Drug Administration (FDA) clearance for its self-fitting hearing aid by providing its 510(k) submission to the FDA. This follows completion of Nuheara’s successful clinical trial by National Acoustic Laboratories (NAL) in January 2022. The trial successfully validated the effectiveness of the Nuheara self-fitted hearing aids compared to
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...